CSL New Zealand INTRAGAM 10 normal immunoglobulin (human) 10g/100mL solution for injection vial

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

human immunoglobulin G, Quantity: 10 g

Disponibbli minn:

CSL Behring Australia Pty Ltd

INN (Isem Internazzjonali):

human immunoglobulin G

Għamla farmaċewtika:

Injection, solution

Kompożizzjoni:

Excipient Ingredients: glycine; human immunoglobulin A

Rotta amministrattiva:

Intravenous Infusion

Indikazzjonijiet terapewtiċi:

Intragam 10 is indicated for replacement IgG therapy in: - primary immunodeficiency disease (PID) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. Intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - Kawasaki disease - Guillain-Barr? syndrome (GBS) - chronic inflammatory demyelinating polyneuropathy (CIDP) - multifocal motor neuropathy (MMN) - myasthenia gravis (MG) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe MG when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic Lambert-Eaton myasthenic syndrome (LEMS) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Sommarju tal-prodott:

Visual Identification: Clear or slightly opalescent and colourless or pale yellow solution.; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Listed (Export Only)

Data ta 'l-awtorizzazzjoni:

2012-08-10